Treatment of CML with tyrosine kinase inhibitors including imatinib, nilotinib, and dasatinib can be associated with subclinical pulmonary hypertension. (Source: CancerNetwork)
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2ocCZ1j
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου